Tag Archives: CABA

Chardan Capital Sticks to Their Buy Rating for Cabaletta Bio (CABA)

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Cabaletta Bio (CABA – Research Report) today and set a price target of $21.00. The company’s shares closed last Monday at $12.48. According to TipRanks.com, Livshits is a top 100

Evercore ISI Thinks Cabaletta Bio’s Stock is Going to Recover

Evercore ISI analyst Joshua Schimmer maintained a Buy rating on Cabaletta Bio (CABA – Research Report) on August 6 and set a price target of $28.00. The company’s shares closed last Friday at $7.14, close to its 52-week low of

Cabaletta Bio (CABA) Receives a Rating Update from a Top Analyst

Chardan Capital analyst Geulah Livshits reiterated a Buy rating on Cabaletta Bio (CABA – Research Report) today and set a price target of $21.00. The company’s shares closed last Thursday at $13.07. According to TipRanks.com, Livshits is a top 25

Analysts Offer Insights on Healthcare Companies: Cabaletta Bio (NASDAQ: CABA), COMPASS Pathways (NASDAQ: CMPS) and Seres Therapeutics (NASDAQ: MCRB)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Cabaletta Bio (CABA – Research Report), COMPASS Pathways (CMPS – Research Report) and Seres Therapeutics (MCRB – Research Report) with bullish sentiments.

Cowen & Co. Initiates a Buy Rating on Cabaletta Bio (CABA)

Cabaletta Bio (CABA – Research Report) received a Buy rating from Cowen & Co. analyst Phil Nadeau today. The company’s shares closed last Monday at $13.79. According to TipRanks.com, Nadeau is a 4-star analyst with an average return of 3.2%